Literature DB >> 21461798

["Dying nevus" or regressing melanoma].

I Zalaudek1, P Donati, C Catricalà, G Argenziano.   

Abstract

Epidemiological studies suggest that the number of acquired melanocytic nevi increases from puberty until midlife and, thereafter, decreases. The latter phenomenon is related to spontaneous involution/apoptosis of nevi. The widespread use of dermoscopy has enriched profoundly our knowledge of the morphological variability of nevi during their evolution. A peripheral symmetric rim of small grown globules represents a clear sign of nevus growth. Instead, nevi in adults often reveal a reticular or reticular-mixed pattern. In patients aged 30 to 40 years clinically vanishing nevi can be noticed, which represent nevi during involution. The important differential diagnoses are melanocytic nevi and melanoma with regression. The life cycle of a nevus is also reflected by the phrase" we are born and we die without nevi".

Entities:  

Mesh:

Year:  2011        PMID: 21461798     DOI: 10.1007/s00105-010-2108-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

1.  Pathways to involution of nevi: insights from dermoscopic follow-up.

Authors:  Vitaly Terushkin; Alon Scope; Allan C Halpern; Ashfaq A Marghoob
Journal:  Arch Dermatol       Date:  2010-04

2.  Natural history of dysplastic nevi.

Authors:  A C Halpern; D Guerry; D E Elder; B Trock; M Synnestvedt; T Humphreys
Journal:  J Am Acad Dermatol       Date:  1993-07       Impact factor: 11.527

3.  Frequency and characteristics of enlarging common melanocytic nevi.

Authors:  H Kittler; M Seltenheim; M Dawid; H Pehamberger; K Wolff; M Binder
Journal:  Arch Dermatol       Date:  2000-03
  3 in total
  1 in total

1.  An unusual case of compound naevus of the scalp with hair greying, suggesting melanoma in dermoscopy.

Authors:  Grazyna Kaminska-Winciorek; Iris Zalaudek; Zdzislaw Wozniak; Maciej Baglaj
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.